Pentoxifylline in Dermatology: Mechanisms of Action, Clinical Applications, and Emerging Therapeutic Perspectives
Abstract
Background: Pentoxifylline (PTX) is a methylxanthine derivative and nonselective phosphodiesterase inhibitor originally introduced for peripheral vascular disease and intermittent claudication. Its ability to improve erythrocyte deformability, reduce blood viscosity and platelet aggregation, enhance microcirculatory flow, and modulate inflammatory and fibrotic pathways has encouraged its use in dermatology. PTX increases intracellular cyclic adenosine monophosphate and suppresses tumor necrosis factor alpha and other proinflammatory cytokines, while reducing leukocyte adhesion, oxidative stress, fibroblast proliferation, and extracellular matrix production. These combined hemorheological, anti-inflammatory, immunomodulatory, and antifibrotic actions provide a rationale for its application in disorders characterized by vascular compromise, chronic inflammation, or excessive fibrosis. Reported dermatological indications include venous leg ulcers, livedoid vasculopathy, pigmented purpuric dermatoses, Behçet disease, leprosy reactions, psoriasis, graft-versus-host disease, sarcoidosis, actinic prurigo, alopecia areata, lipodermatosclerosis, necrobiosis lipoidica, pretibial myxedema, keloids, hypertrophic scars, morphea, and systemic sclerosis. PTX has also been evaluated as adjunctive therapy in leishmaniasis, oral submucous fibrosis, radiation-induced fibrosis, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Although generally well tolerated and inexpensive, evidence varies considerably between indications, and many applications rely on small studies or case reports. Further controlled trials are required to establish optimal dosing, long-term safety, and comparative clinical effectiveness across diverse dermatological populations and clinical practice settings.